Key facts
- 1nhaler’s last known valuation is $13.8M (Nov 2025).
- It has raised $4.5M; the latest was Later Stage VC ($1.9M) in Nov 2025.
- Notable investors include Scottish Enterprise, British Business Investments, Archangel Investors, Yusuf Hamied.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for 1nhaler
- ·The full record, as it builds
Funding rounds
No funding rounds for 1nhaler are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 1nhaler
Developer of a dry powder inhaler designed to assist with inhalable medications. The company offers a breath-activated, low-cost disposable cardboard device that uses a breathable membrane to store the relevant drug within the device to avoid the issue of agglomeration and provide convenient single-dose inhalers, enabling customers to replace traditional inhalers with portable, distributable, and recyclable alternatives and access life-saving inhalable drugs.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2017
- Employees
- 5
- Website
- 1nhaler.com/
- Ownership
- Privately Held (backing)
1nhaler doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 1nhaler shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 1nhaler in its N-PORT filings yet. We sweep new filings monthly.